Cargando…
A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma
OBJECTIVE: Despite the availability of new agents, elderly patients with multiple myeloma (MM) usually present with poor outcomes due to the heterogeneity of disease conditions, especially immune deficiency. Regulatory B cells (Bregs) can be involved in immune defects by exerting immune regulatory f...
Autores principales: | Tang, Wenjiao, Li, Yan, Zou, Zhongqing, Cui, Jian, Wang, Fangfang, Zheng, Yuhuan, Hou, Li, Pan, Ling, Xiang, Bing, Chang, Hong, Zhang, Li, Niu, Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939179/ https://www.ncbi.nlm.nih.gov/pubmed/36127626 http://dx.doi.org/10.1002/cam4.5228 |
Ejemplares similares
-
Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma
por: Cui, Jian, et al.
Publicado: (2021) -
Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China
por: Zou, Zhongqing, et al.
Publicado: (2021) -
Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum
por: Zou, Zhongqing, et al.
Publicado: (2022) -
Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma
por: Huang, Hao, et al.
Publicado: (2023) -
Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)